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Objectives. The present study investigated current management
strategies as well as the clinical course of acute major pulmonary
embolism.
Background. The clinical outcome of patients with acute pul-
monary embolism who present with overt or impending right
heart failure has not yet been adequately elucidated.
Methods. The 204 participating centers enrolled a total of 1,001
consecutive patients. The inclusion criteria were based on the
clinical findings at presentation and the results of electrocardio-
graphic, echocardiographic, nuclear imaging and cardiac cathe-
terization studies.
Results. Echocardiography was the most frequently performed
diagnostic procedure (74%). Lung scan or pulmonary angiogra-
phy were performed in 79% of clinically stable patients but much
less frequently in those with circulatory collapse at presentation
(32%, p < 0.001). Thrombolytic agents were given to 478 patients
(48%), often despite the presence of contraindications (193 [40%]
of 478). The frequency of initial thrombolysis was significantly
higher in clinically unstable than in normotensive patients (57%
vs. 22%, p < 0.001). Overall in-hospital mortality rate ranged
from 8.1% in the group of stable patients to 25% in those
presenting with cardiogenic shock and to 65% in patients neces-
sitating cardiopulmonary resuscitation. Major bleeding was re-
ported in 92 patients (9.2%), but cerebral bleeding was uncommon
(0.5%). Finally, recurrent pulmonary embolism occurred in 172
patients (17%).
Conclusions. Current management strategies of acute major
pulmonary embolism are largely dependent on the degree of
hemodynamic instability at presentation. In the presence of severe
hemodynamic compromise, physicians often rely on the findings
of bedside echocardiography and proceed to thrombolytic treat-
ment without seeking further diagnostic certainty in nuclear
imaging or angiographic studies.
(J Am Coll Cardiol 1997;30:1165–71)
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The prognosis of acute pulmonary embolism is still poorly
understood (1). Patients with pulmonary embolism who are
not hypotensive or in need of emergency therapeutic proce-
dures, such as thrombolysis or pulmonary embolectomy, gen-
erally have a benign clinical course (2–4). In contrast, in-
hospital mortality is considerably higher in those patients who
present with clinical (5,6) or echocardiographic (7) evidence of
acute right heart failure.
Diagnostic and therapeutic strategies for acute pulmonary
thromboembolism have largely been influenced by the clinical
presentation and the degree of hemodynamic instability of the
patient population studied as well as by the logistics of the
medical arena (8). These interactions are complex, and their
impact on patient management and outcome has been difficult
to assess. In an attempt to resolve these issues, the present
registry focused on current management strategies as well as
on the clinical outcome of patients with major pulmonary
embolism in a large setting of community hospitals. The
objective of the study was to test the following hypotheses: 1)
The extent of diagnostic workup and, in particular, the fre-
quency of nuclear imaging or pulmonary angiographic studies
for definite confirmation of pulmonary embolism decrease as
the severity of hemodynamic instability at presentation in-
creases; 2) patients who are most hemodynamically unstable
(i.e., in cardiogenic shock or in need of cardiopulmonary
resuscitation at the time of diagnosis) are those who most
frequently receive aggressive treatment, especially early throm-
bolysis; and 3) the degree of clinical and hemodynamic insta-
bility due to acute right heart failure is the most important
determinant of in-hospital mortality.
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Methods
Study patients. The Management Strategy and Prognosis
of Pulmonary Embolism Registry (MAPPET) was conducted
between September 1993 and December 1994 (9,10). Within
this time period, the 204 participating centers throughout
Germany (see Appendix) registered a total of 1,001 consecu-
tive patients with a diagnosis of major pulmonary embolism
that was made according to predefined criteria. Inclusion
criteria for entry into the registry included the following
clinical, echocardiographic and cardiac catheterization findings
signifying acute right heart failure or pulmonary hypertension
due to pulmonary embolism, or both: 1) arterial hypotension,
defined as systolic blood pressure ,90 mm Hg or a pressure
drop of at least 40 mm Hg for a time period .15 min, if not
due to new-onset arrhythmia, hypovolemia or sepsis; 2) car-
diogenic shock, in which the presence of arterial hypotension as
defined in criterion 1 was accompanied by clinical signs of
organ hypoperfusion and hypoxia (altered level of conscious-
ness, urine output ,30 ml/h, cold and clammy extremities);
3) circulatory collapse necessitating cardiopulmonary resuscita-
tion; 4) at least two of the following two-dimensional and
Doppler echocardiographic findings indicating acute right
ventricular pressure overload or pulmonary hypertension in
the absence of left ventricular or mitral valve disease (11,12):
a) right ventricular dilation (i.e., right ventricle appearing
larger than the left ventricle from the apical or subcostal
view), b) paradoxic septal wall motion, c) loss of inspiratory
collapse of inferior vena cava, d) tricuspid regurgitation jet
velocity .2.8 m/s or .2.5 m/s in the absence of inspiratory
collapse of the inferior vena cava; and 5) diagnosis of
precapillary pulmonary hypertension (mean pulmonary artery
pressure .20 mm Hg in the presence of normal pulmonary
artery occlusion pressures) by right heart catheterization.
Patients with clinically suspected pulmonary embolism were
included in the registry if they met at least one of the criteria
1 to 5 at presentation, together with: 1) a diagnostic pulmonary
angiogram, or 2) a lung scan indicating high probability of
pulmonary embolism, or 3) at least three of the following
findings obtained from clinical examination, blood gas anal-
ysis or the electrocardiogram (ECG): a) syncope; b) tachy-
cardia (heart rate .100 beats/min); c) dyspnea or tachypnea
(.24 breaths/min or need for mechanical ventilation) or
both; d) arterial hypoxemia (partial arterial pressure of
oxygen ,70 mm Hg while breathing room air or ,80 mm Hg
under supplemental oxygen of at least 2 liters/min) in the
absence of pulmonary infiltrates on chest x-ray film; and e)
ECG signs of right heart strain (at least one of the following:
complete or incomplete right bundle branch block, S waves in
lead I combined with Q waves in lead III or T wave inversion
in the precordial leads V1 to V3). Patients were not included in
the registry if tachycardia or hypotension was judged to be due
to hypovolemia or sepsis, or if acute respiratory failure could
be explained by the presence of extensive pulmonary infiltrates
on chest X-ray film.
All decisions concerning the diagnostic workup and treat-
ment were made by the clinicians caring for each patient. The
steering committee took every care not to exert any influence
on the management strategy followed in the participating
hospitals.
Data acquisition. Complete information on the clinical
course as well as the diagnostic and therapeutic management
of the patients entering the registry was obtained by means of
a standardized questionnaire (case report form) sent to the
participating centers by the steering committee. Data were
collected on 1) clinical symptoms and signs of the patients at
diagnosis, including arterial blood gases and chest roentgeno-
grams; 2) presence of underlying diseases or predisposing
factors for pulmonary thromboembolism; 3) findings of the
diagnostic procedures performed for confirmation of right
heart pressure overload or direct imaging of the embolic
obstruction, including ECG, echocardiographic and nuclear
imaging studies; right heart catheterization and pulmonary
angiography; 4) treatment given to patients (heparin anticoag-
ulation, thrombolysis, surgical pulmonary embolectomy, cath-
eter thrombus fragmentation, caval filter implantation); and 5)
in-hospital clinical course of patients (duration of hospital stay,
recurrent venous or arterial thromboembolic events, bleeding
complications, medication on discharge from the hospital or
causes of death and autopsy findings for those who died in the
hospital phase). Major bleeding was prospectively defined as
bleeding that required red cell transfusions or discontinuation
of treatment, or as hemorrhagic stroke confirmed by computed
tomography or autopsy.
Definition of patient groups. The consensus conference of
the steering committee prospectively defined four patient
groups of increasing clinical and hemodynamic instability,
indicating increasing severity of acute right heart failure:
Group 1 5 Patients with acute pulmonary embolism and
evidence of right ventricular pressure overload or pulmonary
hypertension on the echocardiogram, or with confirmation of
precapillary pulmonary hypertension on right heart catheter-
ization, in the absence of arterial hypotension at presentation.
Group 2 5 Patients presenting with arterial hypotension
(systolic blood pressure ,90 mm Hg or a pressure drop of at
least 40 mm Hg for a time period .15 min) but without clinical
signs of cardiogenic shock or the need for catecholamine
support of blood pressure (except for dobutamine, #5 mg/kg
body weight per min). Group 3 5 Patients with arterial
hypotension accompanied by cardiogenic shock or judged by
the attending physicians to require the administration of
catecholamines. Group 4 5 Patients with circulatory collapse
who underwent cardiopulmonary resuscitation at presentation.
The study patients were classified into one of these four
Abbreviations and Acronyms
ECG 5 electrocardiogram, electrocardiographic
UPET 5 Urokinase in Pulmonary Embolism Trial
PIOPED 5 Prospective Investigation of Pulmonary Embolism
Diagnosis
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groups by the coordinating center at study entry. To avoid
selection bias, the collaborating physicians were unaware of
this classification during the recruitment phase.
Statistical analysis. For descriptive purposes, mean val-
ues 6 SD were calculated for continuous variables and abso-
lute and relative frequencies for discrete variables. Differences
between characteristics of the patient groups were univariately
tested for significance by means of the Fisher exact test for
discrete variables and the Kruskal-Wallis rank test for contin-
uous variables. Multiple logistic regression was used to inves-
tigate the independent effect of clinical characteristics at
presentation on the extent of diagnostic workup (i.e., on
whether lung scan or pulmonary angiography was performed
for definite confirmation of pulmonary embolism) (13). Only
those variables that reached p , 0.2 in univariate testing were
considered in the multiple logistic regression model. Data
processing and analysis were performed with the Statistical
Analysis System (SAS). All significance tests were two-tailed,
with p , 0.05 considered to indicate statistical significance.
Results
The clinical characteristics of 1,001 patients with major
pulmonary embolism who fulfilled the entry criteria are shown
in Table 1. The mean age of the patients at diagnosis was 63 6
15 years. Most patients (70%) had an acute onset of symptoms
(,48 h), and 784 (78%) had at least one known risk factor for
venous thromboembolism in their history.
Diagnostic strategy. The absolute and relative frequencies
with which invasive and noninvasive diagnostic methods were
used in each group are shown in Table 2. The majority of the
registry patients (74%) underwent two-dimensional and Dopp-
ler echocardiographic studies. The presence of right heart
pressure overload or pulmonary hypertension, or both, was
thus established in 303 Group 1 patients (74%), 221 Group 2
patients (70%), 69 Group 3 patients (68%) and 115 Group 4
patients (65%). In contrast, 227 study patients (23%) had
invasive confirmation of pulmonary hypertension by right heart
catheterization.
Thromboembolic pulmonary vessel occlusion was con-
firmed by angiography in 174 patients (17%), by a high
probability lung scan in 549 (55%) and by at least one of these
imaging studies in 68% of the patients included in the present
registry. However, performance of angiographic or scinti-
graphic studies strongly depended on the severity of clinical
and hemodynamic instability at presentation, ranging from
79% in Group 1 to 32% in Group 4 (p , 0.001). Overall, the
number of diagnostic studies performed (Table 2) decreased
from 3.9 procedures/patient in Group 1 to 2.6 procedures/
patient in Group 4 (p , 0.001).
As shown in Table 3, age .65 years, acute onset of
Table 1. Clinical Findings at Diagnosis in 1,001 Study Patients
Age .65 yr 516 (52)
Men/women 590/411
Ratio 1.43:1
Acute onset of symptoms (,48 h) 696 (70)
Dyspnea 958 (96)
Syncope 354 (35)
Tachycardia (pulse rate .100/min) 710 (71)
Arterial hypotension (SBP ,90 mm Hg) 341 (34)
Recent major operation (within 10 days) 274 (27)
Recent major trauma or fracture (within 10 days) 106 (11)
Pregnant 14 (1.4)
History of
Venous thrombosis 289 (29)
Pulmonary embolism 117 (12)
Congestive heart failure 316 (32)
Chronic pulmonary disease 105 (11)
Cancer 122 (12)
Stroke 22 (2.2)
Data presented are number (%) of patients, unless otherwise indicated.
SBP 5 systolic blood pressure.
Table 2. Diagnostic Workup
Diagnostic
Method
Group 1
(n 5 407)
Group 2
(n 5 316)
Group 3
(n 5 102)
Group 4
(n 5 176)
ECG 405 (99.5%) 312 (99%) 102 (100%) 162 (92%)
Echo 325 (80%) 230 (73%) 69 (68%) 117 (66%)
Lung scan 278 (68%) 189 (60%) 58 (57%) 42 (24%)
Right heart cath 119 (29%) 73 (23%) 26 (26%) 43 (24%)
Pulm angio 92 (23%) 46 (15%) 14 (14%) 24 (14%)
Search for DVT
(B-mode and/or
Doppler US or
phlebography)
357 (88%) 248 (79%) 76 (75%) 70 (40%)
Data presented are number (%) of patients. Cath 5 catheterization; DVT 5
deep venous thrombosis; Echo 5 echocardiogram; ECG 5 electrocardiogram;
Pulm angio 5 pulmonary angiogram; US 5 ultrasound. See Methods for
explanation of study groups.
Table 3. Baseline Clinical Findings and Severity of Hemodynamic
Instability in Patients With and Without Lung Scan or
Pulmonary Angiogram*
Pts Without
Lung Scan/
Pulm Angio
(n 5 334)
Pts With
Lung Scan/
Pulm Angio
(n 5 648)
p
Value
Age .65 yr 195 (58%) 313 (48%) 0.003
Acute onset of
symptoms†
263 (79%) 419 (65%) , 0.001
Arterial hypotension
(SBP , 90 mm Hg)
243 (73%) 322 (50%) , 0.001
Tachycardia (pulse rate
. 100/min)
259 (78%) 436 (67%) , 0.001
Need for catecholamines 138 (41%) 106 (16%) , 0.001
Endotracheal intubation 106 (32%) 44 (6.8%) , 0.001
Cardiopulmonary
resuscitation
87 (26%) 30 (4.6%) , 0.001
*Only those clinical characteristics for which statistically significant differ-
ences were found by univariate analysis are included. †Onset of symptoms was
defined as acute if it preceded diagnosis of pulmonary embolism by not more
than 48 h. Data presented are number (%) of patients (Pts). Other abbreviations
as in Tables 1 and 2.
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symptoms (within 48 h), clinical signs of hemodynamic insta-
bility (tachycardia, arterial hypotension, need for catechol-
amine support of blood pressure) and cardiopulmonary resus-
citation were all found by univariate analysis to be significantly
more frequent in patients without definite confirmation of
pulmonary embolism by lung scan or angiography. Multiple
logistic regression analysis revealed that diagnosis of major
pulmonary embolism at the bedside (i.e., based on clinical
findings and echocardiography) was independently associated
with the following clinical characteristics at presentation: age
.65 years (p 5 0.001), pregnancy (p 5 0.033), arterial
hypotension (p , 0.001), tachycardia (p , 0.001), need for
endotracheal intubation (p 5 0.003) and need for cardiopul-
monary resuscitation (p 5 0.009).
Treatment of pulmonary embolism. Almost every patient
included in the present study received specific treatment for
pulmonary embolism (Table 4). In addition to conventional
anticoagulation with heparin in doses adjusted to achieve
therapeutic prolongation of the activated partial thromboplas-
tin time (95% of patients), 478 patients (48%) underwent
thrombolytic treatment. Early thrombolysis (i.e., within 24 h of
diagnosis of pulmonary embolism) was more frequently per-
formed in patients with hemodynamic instability at presenta-
tion (57% Group 3 or 4 patients) than in patients with more
hemodynamic stability belonging to Group 1 or 2 (22%, p ,
0.001). As shown in Table 5, the attending physicians fre-
quently judged that the severity of pulmonary embolism war-
ranted the use of thrombolytic agents, even in the presence of
contraindications to thrombolysis.
After diagnosis of venous thromboembolism, a caval filter
was implanted more frequently in Group 1 or 2 patients than
in Group 3 or 4 patients (6.4 vs. 1.8%, p , 0.001). Finally, more
aggressive therapeutic procedures, such as catheter thrombus
fragmentation or emergency surgical embolectomy, were per-
formed only in isolated cases (Table 4).
In-hospital course and mortality. The overall in-hospital
mortality rate was 22%. There was a substantial increase in the
mortality rate from 8.1% in patients with hemodynamic stabil-
ity at presentation (Group 1) to 65% in patients necessitating
cardiopulmonary resuscitation (Group 4: p , 0.001 vs. Group
1). In most cases (91%), death occurring during the in-hospital
phase was directly related to the thromboembolic event. Only
few patients died of their underlying disease or due to com-
plications of diagnostic or therapeutic procedures (0.9% and
1.0%, respectively).
Patients with definite confirmation of pulmonary embolism
by pulmonary angiography or lung scan had a mortality rate of
11% as opposed to 45% in those patients in whom these
diagnostic procedures were not performed (p , 0.001). The
mortality of patients with and without scintigraphic or angio-
graphic confirmation of pulmonary embolism within each
group is shown in Figure 1.
Clinically apparent recurrence of pulmonary embolism was
diagnosed in 172 study patients (17%). The recurrence rates
were similar among the four patient groups. Arterial throm-
boembolic events as well as cerebral hemorrhage were ob-
served in few patients in each group. Finally, the occurrence of
other major bleeding episodes requiring red cell transfusions
or discontinuation of treatment ranged from 7.4% to 12%
(Table 6).
Discussion
In-hospital mortality of patients with major pulmonary
embolism. Most previous trials on pulmonary embolism in-
cluded hemodynamically stable patients who were able to
tolerate an extensive diagnostic workup, including ventilation–
Table 4. Treatment of Acute Major Pulmonary Embolism
Treatment
Group 1
(n 5 407)
Group 2
(n 5 316)
Group 3
(n 5 102)
Group 4
(n 5 176)
Heparin anticoagulation 399 (98%) 302 (96%) 95 (93%) 153 (87%)
Thrombolysis
Early* 93 (23%) 68 (22%) 41 (40%) 117 (67%)
Late 79 (19%) 58 (18%) 4 (3.9%) 18 (10%)
Surgical embolectomy 2 (0.5%) 3 (1%) 1 (1.0%) 2 (1.1%)
Thrombus fragmentation 7 (1.7%) 4 (1.3%) 3 (2.9%) 12 (6.8%)
Caval filter implantation 30 (7.4%) 16 (5.1%) 1 (1.0%) 4 (2.3%)
No specific treatment 3 (0.7%) 2 (0.6%) 0 5 (2.8%)
*Defined as thrombolytic treatment within 24 h of diagnosis of pulmonary embolism. Data presented as number (%)
of patients.
Table 5. Contraindications to Thrombolytic Treatment in 1,001
Registry Patients
Contraindication Present*
Thrombolytic Treatment
Despite Contraindication†
Age .75 yr 194 (19) 57 (29)
Recent major operation‡ 111 (11) 38 (34)
Recent major trauma‡ 27 (2.7) 14 (52)
Pregnancy 14 (1.4) 6 (43)
Cancer 122 (12) 41 (34)
Previous stroke 22 (2.2) 4 (18)
Cardiopulmonary
resuscitation
118 (12) 88 (75)
At least 1 of the above 474 (47) 193 (41)
*Number (%) of study patients. †Number (%) of subgroup. ‡As in Table 1.
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perfusion lung scan or pulmonary angiography, or both, for
definite confirmation of pulmonary embolism (4,14,15). In
contrast, the patients included in the present registry had
major pulmonary embolism according to prospectively defined
clinical and hemodynamic criteria. Overall, 93% of our pa-
tients had confirmation of pulmonary artery hypertension by
right heart catheterization or evidence for acute right heart
strain provided by ECG or echocardiographic findings. Fur-
thermore, 28% of the patients were hemodynamically unstable
at presentation, requiring catecholamine support of blood
pressure or even cardiopulmonary resuscitation. The in-
hospital mortality rate of this patient cohort was 22%, which is
in accordance with the high (18% to 33%) mortality rates
reported by other investigators in patients with massive pul-
monary embolism (6,16) and considerably higher than the 8%
and 9.5% mortality rate of the hemodynamically stable pa-
tients included in the Urokinase in Pulmonary Embolism Trial
(UPET) (14) and Prospective Investigation of Pulmonary
Embolism Diagnosis (PIOPED) (15) trial, respectively.
Impact of hemodynamic instability on diagnostic workup.
The mortality of patients in whom lung scan or pulmonary
angiography was performed to confirm pulmonary embolism
was 11%, much lower than the 45% mortality rate of the
patients in whom the diagnosis of acute pulmonary embolism
was made on the basis of high clinical suspicion supported by
echocardiographic signs of acute right heart pressure overload.
The reason for the unfavorable outcome of the patients not
undergoing scintigraphic or angiographic procedures was
shown to be their hemodynamic instability at presentation,
which prohibited extensive diagnostic workup. Certainly, diag-
nostic inaccuracy of bedside clinical and echocardiographic
evaluation alone remains a possibility in some of these unsta-
ble patients. In contrast, the low mortality of the patients who
underwent nuclear imaging or angiographic studies in our
registry closely approaches the mortality of the patients in the
UPET (14) and PIOPED (15) trials and thus indicates that
diagnostic strategies seeking definite confirmation of pulmo-
nary embolism may lead to “selection” of a patient cohort with
a relatively benign clinical outcome.
That the majority (74%) of the registry patients underwent
echocardiography at presentation signifies an important trend
in the diagnostic approach to patients with clinically suspected
pulmonary embolism. Bedside echocardiography, aided by the
ECG and chest X-ray findings, is a useful tool for differential
diagnosis between acute pulmonary embolism and other po-
tentially life-threatening cardiovascular or pulmonary disor-
ders (e.g., acute myocardial infarction, pericardial tamponade,
aortic dissection or fulminant pneumonia). Moreover, it per-
mits rapid, noninvasive and reliable detection of right heart
pressure overload resulting from major pulmonary embolism
(12). This information is of particular importance for risk
stratification of patients (7,9,17) as well as for identification of
potential candidates for thrombolytic treatment (10,18,19).
The frequency of search for deep-vein thrombosis by non-
invasive or phlebographic studies was 88% in clinically stable
patients but remained high even in the group with initial
hypotension (75%). This practice obviously emphasizes the
Figure 1. Overall in-hospital mortality in patients with confirmation of
pulmonary embolism by lung scan or pulmonary angiography (hatched
bars) compared with mortality rate in patients who did not undergo
these procedures (solid bars). Numbers above bars denote percent of
patients in each group. See Methods for explanation of study groups.
Table 6. In-Hospital Clinical Course
Event
Group 1
(n 5 407)
Group 2
(n 5 316)
Group 3
(n 5 102)
Group 4
(n 5 176)
Overall mortality 33 (8.1%) 48 (15%) 25 (25%) 114 (65%)
Death due to PE 29 (7.1%) 43 (14%) 23 (23%) 106 (60%)
Death due to underlying disease 3 (0.7%) 3 (1.0%) 1 (1.0%) 2 (1.1%)
Death due to complications of
diagnostic procedures or
treatment
1 (0.3%) 2 (0.6%) 1 (1.0%) 6 (3.4%)
Nonfatal events
Recurrent PE 57 (14%) 61 (19%) 22 (22%) 32 (18%)
Arterial thromboembolism 5 (1.2%) 4 (1.3%) 0 5 (2.8%)
Cerebral bleeding 1 (0.3%) 3 (1.0%) 0 1 (0.6%)
Other major bleeding* 30 (7.4%) 24 (7.6%) 12 (12%) 21 (12%)
*Bleeding requiring red cell transfusion or discontinuation of therapeutic anticoagulation or thrombolytic treatment.
Data presented are number (%) of patients. PE 5 pulmonary embolism.
1169JACC Vol. 30, No. 5 KASPER ET AL.
November 1, 1997:1165–71 MANAGEMENT STRATEGIES IN PULMONARY EMBOLISM
concern of clinicians for the presence of a significant periph-
eral venous clot burden and the risk of recurrent pulmonary
embolism (20).
Treatment of major pulmonary embolism. Nearly every
second patient included in the present study received a throm-
bolytic agent. The rate of thrombolytic treatment (48%) was
thus much higher than the 6% rate reported in the PIOPED
study (15). This difference can be attributed to the hemody-
namic instability of our patient cohort, as well as to the
echocardiographic demonstration of right heart pressure over-
load in most of our patients. Both factors are regarded as
indications for thrombolytic therapy in patients with acute
pulmonary embolism (18,19), although a favorable effect of
thrombolysis on patient outcome in this setting remains to be
confirmed by a prospective, randomized trial (21,22). As
hypothesized, the frequency of thrombolytic treatment in our
patients was strongly associated with the degree of clinical
instability at presentation and was as high as 77% in the most
unstable group. In contrast, catheter thrombus fragmentation
or surgical pulmonary embolectomy was performed infre-
quently, even in the most unstable patient group or in those
patients with contraindications to thrombolysis. These emer-
gency procedures thus seem to play a minor role in the setting
of community hospitals.
In almost every fifth patient in Group 1 or 2 (i.e., in those
patients who did not require catecholamine support of arterial
blood pressure), the initial treatment with intravenous heparin
anticoagulation was subsequently changed in favor of a throm-
bolytic regimen. This policy might either reflect a treatment
failure of heparin or the uncertainty of the clinicians when
confronted with hemodynamically stable patients with acute
pulmonary embolism and evidence of right heart pressure
overload. From our data it was not possible to clarify this issue,
which will have to be addressed by future trials.
Finally, the observation that pulmonary embolism occurred
within 10 days of major operation in as many as 27% of our
patients is certainly disturbing and implies that much further
work is needed to prevent postoperative pulmonary embolism.
Conclusions. The present registry demonstrates that the
management strategy and in-hospital outcome of patients with
major pulmonary embolism is closely related to the severity of
hemodynamic instability at the time of presentation. Increasing
clinical instability results in a decrease in the frequency with
which lung scans or invasive pulmonary angiograms are ob-
tained to definitely confirm pulmonary embolism. Increasing
clinical instability also urges physicians to proceed to “rescue”
thrombolytic treatment, even in the presence of contraindica-
tions to thrombolysis. To our knowledge, the results of the
present study thus provide, for the first time, an accurate
reflection of current management strategies in patients with
major pulmonary embolism. Furthermore, these results can
prove especially helpful in planning prospective, randomized
trials that will clarify the impact of widely used treatment
modalities, especially thrombolysis, on the outcome of patients
with acute pulmonary embolism.
Appendix
Participating Centers and Physicians for the
Management and Prognosis of Pulmonary
Embolism Registry (Germany)
Luisen-Hospital, Aachen: Dr. J. Ontyd, Dr. D. Wolter; Kreiskrankenhaus
Achern: Dr. P. Reimling; Kreiskrankenhaus Altenburg: Dr. J. Janitschek;
Kreiskrankenhaus am Plattenwald, Bad Friedrichshall: Dr. N. Ro¨hrig; Evange-
lisches Krankenhaus Bad Gandersheim: Dr. R. Zahn; Caritas Krankenhaus Bad
Mergentheim: Dr. H. Bechtold, Dr. Haag, Dr. N. Heller, Dr. M. Klein; William
Harvey Klinik, Bad Nauheim: Dr. Stahl; Schu¨chtermann-Klinik, Bad Rothen-
felde: Dr. W. Kranig; Kreiskrankenhaus Bad Urach: Dr. T. Antenrieth, Dr. B.
Jung; Stadtklinik Baden-Baden: Dr. W. Kaschner, Dr. L. Le´vai; Krankenhaus
Ballenstedt: Dr. B. U. Franz; Krankenhaus Hohe Warte, Bayreuth: Dr. J.
Kothmann; Klinikum Bayreuth: Dr. Mang, Dr. S. Schmitt; Evangelisches Kran-
kenhaus Bergisch Gladbach: Dr. H. J. Schmitz, Dr. P. Schweizer; Marienkran-
kenhaus Bergisch Gladbach: Dr. S. Hinzmann; Krankenhaus im Friedrichshain:
Dr. U. Abet; Universita¨tsklinikum Rudolf Virchow, Berlin: Dr. D. Gulba, Dr.
H. J. Kleiner, Dr. S. Kubitza; Humboldt-Krankenhaus, Berlin: Dr. R. Bartels, Dr.
Mazur, Dr. U. Pohlmann, Dr. J. Weber; DRK Kliniken Westend, Berlin: Dr. J. F.
Schro¨der; Krankenhaus Bethel, Berlin: Dr. A. Stolper; Malteser-Krankenhaus,
Berlin: Dr. L. Wieczorkowski; Sta¨dtische Krankenanstalten Bielefeld-Mitte: Dr.
B. Leeuw; Sta¨dtisches Krankenhaus Bietigheim: Dr. D. Hey; Heilig-Geist-
Hospital, Bingen: Dr. W. Schmidt; St. Josef Hospital, Bochum: Dr. Bo¨ckenfo¨rde;
Augusta-Kranken-Anstalt, Bochum-Linden: Dr. Lessmann; Berufsgenossen-
schaftliche Kliniken Bergmannsheil, Bochum: Dr. Machraoui; Universita¨tsklinik
Bonn: Dr. T. Brecht; Evangelisches Krankenhaus Bonn-Bad Godesberg: Dr. J. v.
Du¨sterlho; St. Marien-Hospital, Bonn: Dr. S. Kern, Dr. Runkel; St. Petrus-
Krankenhaus, Bonn: Dr. H. Hu¨neburg; Sta¨dtisches Klinikum Brandenburg: Dr.
U. Huber; Sta¨dtisches Klinikum Braunschweig: Dr. Kooymann; Zentralkranken-
haus Bremen-Nord: Dr. W. Bu¨rgener; Zentralkrankenhaus Bremen-Ost: Dr. T.
Hilmer; Krankenhaus Bruchsal: Dr. M. Braun, Dr. J. Koster; Kreiskrankenhaus
Buchen: Dr. Rauchenbach, Dr. H. Ribwitzky, Dr. Zo¨ll; Kreiskrankenhaus
Burghausen: Dr. Saswatendu, Dr. S. Sarkar; Kreiskrankenhaus Burglenfeld: Dr.
F. J. Riedhammer; Lukas-Krankenhaus, Bu¨nde: Dr. D. Brunswig, Dr. M.
Hilgedieck; Evangelisches Krankenhaus Castrop-Rauxel: Dr. W. Jaedicke;
Sta¨dtische Kliniken Chemnitz: Dr. T. Vieth; St. Josefs-Hospital, Cloppenburg:
Dr. A. Bleuer; St. Vincenz-Hospital, Coesfeld: Dr. M. Greguletz; Sta¨dtische
Kliniken Darmstadt: Dr. Evers; St. Vincenz-Krankenhaus, Datteln: Dr. R. Gru¨n;
Kreiskrankenhaus Demmin: Dr. V. Bru¨mmer; Herz-Jesu-Krankenhaus, Dern-
bach: Dr. M. Schollen; Klinikum Lippe-Detmold: Dr. U. Tebbe; Krankenhaus St.
Elisabeth, Dillingen: Dr. Emmert; Evangelisches Krankenhaus Dinslaken: Dr.
R. O. Scheemann; Katholisches Krankenhaus Dortmund-West: Dr. U. Han-
heide; Sta¨dtische Kliniken Dortmund: Dr. K. Sondern; Krankenhaus Du¨ren: Dr.
G. Hanenberg, Dr. E. von der Lohe, Dr. W. Winkels; Krankenhaus Ebersbach:
Dr. B. Neumann; Kreiskrankenhaus Ehingen: Dr. B. Platt; Kreiskrankenhaus
Ellwangen: Dr. Dietterle; Kreiskrankenhaus Emmendingen: Dr. S. Bo¨lch;
Medizinische Hochschule Erfurt: Dr. C. Schubert, Dr. G. Vogel; Alfried Krupp
von Bohlen und Halbach Krankenhaus Essen: Dr. M. Benn; St. Markus-
Krankenhaus, Frankfurt/M.: Dr. O. Ludwig; Krankenhaus Sachsenhausen,
Frankfurt/M: Dr. H. Wetzel; Universita¨tsklinik Freiburg: Dr. M. Redecker, Dr.
J. A. Rump; Stadtkrankenhaus Friedberg/Bayern: Dr. A. Stiebens; Bu¨rgerhos-
pital Friedberg/Hessen: Dr. A. Ja¨ckel; Hospital zum Heiligen Geist, Fritzlar: Dr.
W. Beinroth; Kreiskrankenhaus Gaildorf: Dr. Richardt; Universita¨tsklinik Gies-
sen: Dr. F. Nix, Dr. G. Schu¨tterle; Kreiskrankenhaus Rudolf Virchow, Glauchau:
Dr. G. J. Hermsdorf, Dr. K. Meyer; Klinik am Eichert, Go¨ppingen: Dr. M. Egle,
Dr. H. Giesler; Evangelisches Krankenhaus Go¨ttingen-Weende: Dr. K. Wu¨rm;
Klinik fu¨r Innere Medizin der Universita¨t Greifswald: Dr. M. Wierbitzky;
Kreiskrankenhaus Gross-Gerau: Dr. Litschke; Kreiskrankenhaus Gu¨strow: Dr.
S. Duda, Dr. P. Ring; St. Elisabeth-Hospital, Gu¨tersloh: Dr. A. Neuwirth;
Sta¨dtisches Krankenhaus Gu¨tersloh: Dr. H. Heusslein, Dr. Wefers; Evangelis-
ches Krankenhaus Hagen-Haspe: Dr. W. Liman, Dr. P. Peter, Dr. F. Strauch;
Allgemeines Krankenhaus Wandsbek, Hamburg: Dr. Gu¨ttschmidt; Evangelis-
ches Krankenhaus Bethesda, Hamburg: Dr. K. P. Stadler; Krankenhaus Hameln:
Dr. K. Meyne; Marienhospital Hamm: Dr. W. Schu¨rhoff; Universita¨tsklinik
Heidelberg: Dr. Katus, Dr. C. Tiefenbacher; St. Josefskrankenhaus Heidelberg:
Dr. M. Reichardt; Sta¨dtisches Krankenhaus Heilbronn: Dr. J. Cyran, Dr. J.
Berentelg; Paracelsus-Klinik, Henstedt-Ulzburg: Dr. U. Jander-Kleinau, Dr. H.
Krukemeyer; Kreiskrankenhaus Herford: Dr. S. Rosocha; Evangelisches Kran-
kenhaus Herne: Dr. W. Sehnert; St. Elisabeth-Krankenhaus, Hu¨nfeld: Dr. A.
Greiner; von Bodelschwingh-Krankenhaus, Ibbenbu¨ren: Dr. R. Volkmar;
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Sta¨dtische Krankenanstalten Idar-Oberstein: Dr. R. Grossmann; St. Elisabeth-
Hospital, Iserlohn: Dr. M. Bermes; Evangelisches Krankenhaus Bethanien,
Iserlohn: Dr. Lilienbeck; Evangelisches Diakonissen-Krankenhaus, Karlsruhe:
Dr. M. Rohlehr; Krankenhauszweckverband Kaufbeuren-Ostallga¨u: Dr. H.
Meyer-Borchert; Sta¨dtisches Krankenhaus Kiel: Dr. G. Becker; Krankenhaus
Evangelische Stift St. Martin, Koblenz: Dr. N. Kaul; Krankenanstalten Konstanz:
Dr. T. Hannemann; St. Elisabeth-Krankenhaus, Ko¨ln: Dr. J. Schoenemann; St.
Franziskus-Hospital, Ko¨ln: Dr. E. Jennen; Kreiskrankenhaus Ko¨sching: Dr. F.
Lacher; Krankenhaus Maria-Hilf, Krefeld: Dr. M. Dichgans, Dr. P. Ohlert;
Sta¨dtische Krankenanstalten Krefeld: Dr. Knoch, Dr. G. Smits; Kreiskranken-
haus Lahr: Dr. B. Wiedemer; St. Johannis-Krankenhaus Landstuhl: Dr. M.
Vesmanis-Johannes; Dreieich-Krankenhaus Langen: Dr. K. Rudolph; Sta¨dtis-
ches Krankenhaus Lauchhammer: Dr. I. Franke; Kreiskrankenhaus Lehrte: Dr.
C. Hauptmann; Sta¨dtisches Klinikum St. Georg, Leipzig: Dr. F. Mickley, Dr. G.
Thiele; Evangelisches Krankenhaus Lengerich: Dr. Amshoff-Jacobs, Dr. H.
Fromm, Dr. Pfeiff; Kreiskrankenhaus Giessen in Lich: Dr. Borowek, Dr. K. H.
Hohmann; Helmut-G.-Walther-Kreiskrankenhaus, Lichtenfels: Dr. E. Du¨n-
ninger; Kreiskrankenhaus Limbach-Oberfrohna: Dr. M. Schellner; Kreiskran-
kenhaus Lohr/Main: Dr. R. Meininger; Sta¨dtisches Krankenhaus Lo¨rrach: Dr.
M. Frank; St. Marienkrankenhaus, Ludwigshafen: Dr. V. Biliati; Klinikum der
Stadt Ludwigshafen/Rhein: Dr. R. Zahn; Kreiskrankenhaus Lu¨bbecke: Dr. M.
Grosse; Spreewald-Klinik Lu¨bben: Dr. H. Reinhold, Dr. F. Schwertfeger;
Sta¨dtisches Krankenhaus Lu¨neburg: Dr. H. Niederstadt; Mu¨hlenberg-Klinik
Malente: Dr. W. Grote; Kreiskrankenhaus Mallersdorf: Dr. W. Feldmeier;
Klinikum Mannheim: Dr. J. Harenberg; Paracelsus-Klinik Marl: Dr. R. Kla¨hn;
Krankenhaus Ludmillenstift, Meppen/Ems: Dr. H. Hoetz; Kreiskrankenhaus
Merzig: Dr. Jo¨st; Kreiskrankenhaus Miltenberg/Main: Dr. G. Voigt; Klinikum
Minden: Dr. W. Lengfelder; Kamillianer-Krankenhaus Mo¨nchengladbach: Dr.
P. Linsenmann; Stauferklinik Schwa¨bisch Gmu¨nd, Mutlangen: Dr. C. Bu¨ch-
mann; Kreiskrankenhaus Mu¨hlacker: Dr. G. Kleine; Kreiskrankenhaus Mu¨hl-
dorf: Dr. K. Igerl; Kreiskrankenhaus Mu¨llheim: Dr. C. Hans, Dr. Moser;
Kreiskrankenhaus Mu¨nchen-Pasing: Dr. C. Wonkas; Sta¨dtisches Krankenhaus
Mu¨nchen-Neuperlach: Dr. M. Spinner; Kreiskrankenhaus Mu¨nsingen: Dr. Hohl-
stein; Universita¨tsklinik Mu¨nster: Dr. R. Mesters, Dr. H. Ostermann; Clemens-
hospital Mu¨nster: Dr. R. Plagwitz; Klinken St. Elisabeth, Neuburg/Donau: Dr. E.
Huber; St. Josef-Krankenhaus Neunkirchen: Dr. M. Bollen; Ruppiner Klinikum,
Neuruppin: Dr. K. J. Schmailzl; Krankenhaus Hetzelstift, Neustadt: Dr. B.
Menges, Dr. Nitsch, Dr. T. Thu¨rauf; Krankenhaus Nienburg: Dr. A. Roth;
Sta¨dtisches Krankenhaus Norderney: Dr. K. Platte; Klinikum der Stadt Nu¨rn-
berg: Dr. J. Herold; Kreiskrankenhaus Nu¨rtingen: Dr. J. Breuning, Dr. H. H.
Krause; Krankenhaus Oberstdorf: Dr. B. Ricken; Kreiskrankenhaus Offenburg:
Dr. U. Stephinger; Sta¨dtische Kliniken Oldenburg: Dr. Bruns; Paracelsus-
Krankenhaus Ruit, Ostfildern: Dr. G. Spa¨th; Kreiskrankenhaus Otterndorf: Dr.
S. Senger; St. Johannisstift Paderborn: Dr. J. Matzke; Marienhospital Papen-
burg: Dr. H. J. Jantke; Kreiskrankenhaus Peine: Dr. F. Weyn; Sta¨dtisches
Krankenhaus Pforzheim: Dr. H. Vollmer; Krankenhaus Pfullendorf: Dr. D.
Widmann; Klinikum Ernst von Bergmann, Potsdam: Dr. H. Gunold; St. Joseph-
Krankenhaus Pru¨m: Dr. L. Czikajlo; Kreiskrankenhaus Radebeul: Dr. A. Mu¨tze;
Krankenhaus der Barmherzigen Bru¨der, Regensburg: Dr. B. Fichtl, Dr. Nie-
derer; Krankenanstalten der Stadt Remscheid: Dr. U. Fahrenkrog; Kreiskran-
kenhaus Reutlingen: Dr. M. H. Hust, Dr. W. Spengler; Jakobi-Krankenhaus
Rheine: Dr. D. Bauer; Kreiskrankenhaus Riesa: Dr. A. Hedrich; Kreiskranken-
haus Rockenhausen: Dr. H. Burkhardt; Kreiskrankenhaus Rodewisch/
Obergo¨ltzsch: Dr. A. Lambert; Diakoniekrankenhaus Rotenburg: Dr. T. Rich-
ardt; Kreiskrankenhaus Roth: Dr. A. Struntz; Kreiskrankenhaus Rotthal-
mu¨nster: Dr. J. Baum; Krankenhaus Vinzentinum, Ruhpolding: Dr. G. Meurers;
Krankenhaus Saarlouis vom Deutschen Roten Kreuz: Dr. Lehmann; Nordwest
Krankenhaus Sanderbusch, Sande: Dr. R. Keymling; Kreiskrankenhaus
Schkeuditz: Dr. R. Oettel; Krankenhaus Kloster-Grafschaft, Schmallenberg-
Grafschaft: Dr. B. Scho¨nhofer; Leopoldina-Krankenhaus Schweinfurt: Dr. D.
Siebenlist; Klinikum Schwerin: Dr. P. Lazarus; Kreiskrankenhaus Sinsheim: Dr.
M. Bollhorst; Hellmuth-Ulrici-Klinik, Sommerfeld: Dr. B. Schneider, Dr. G.
Schulz; Stadtkrankenhaus Sonthofen/Oberallga¨u: Dr. M. Baumgarten, Dr. H. K.
Giesen; Krankenhaus der Evangelischen Diakonissenanstalt, Speyer: Dr. G.
Tippel; Krankenhaus Stade: Dr. Missler; Klinikum der Hansestadt Stralsund: Dr.
B. Flor, Dr. G. Mu¨ller-Esch; Karl-Olga-Krankenhaus Stuttgart: Dr. W. Pres-
meier; Kreiskrankenhaus Sulingen: Dr. Bokelmann; Kreiskrankenhaus Titisee-
Neustadt: Dr. L. Herkel; Kreiskrankenhaus Traunstein: Dr. W. Drost, Dr. K.
Schlotterbeck; Krankenanstalt Mutterhaus der Borroma¨erinnen, Trier: Dr. H.
Siebner; Marienkrankenhaus Trier: Dr. A. Traut; Kreiskrankenhaus Tuttlingen:
Dr. E. Kauder; Albert-Schweitzer-Krankenhaus Uslar: Dr. Kamrad; Klinikum
der Stadt Villingen-Schwenningen: Dr. Kohler; Krankenhaus St. Michael,
Vo¨lklingen/Saar: Dr. P. Kru¨ger; St. Antonius Krankenhaus, Wegberg: Dr. C.
Ha¨rtel; Kreiskrankenhaus Weinheim: Dr. F. Hoeltermann; Krankenhaus Wer-
meiskirchen: Dr. R. Bo¨hm; Krankenhaus Wettin: Dr. M. Meisel; St. Josefs-
Hospital Wiesbaden: Dr. B. Busse, Dr. Elsner, Dr. A. Furtwa¨ngler, Dr. A.
Meyer, Dr. A. Roth, Dr. M. Werner; Katharinen-Hospital, Willich: Dr.
Krahnsto¨ver; Sta¨dtisches Krankenhaus Wismar: Dr. F. Hauzeur, Dr. S. Plietzsch;
Kreiskrankenhaus Wolfach: Dr. H. H. Braun; Stadtkrankenhaus Wolfsburg: Dr.
B. Gerecke; Stadtkrankenhaus Worms: Dr. A. Mu¨ller, Dr. W. Schmalz; Kran-
kenhaus Marienho¨he, Wu¨rselen: Dr. R. Harlacher; Missionsa¨rztliche Klinik
Wu¨rzburg: Dr. A. Horowitz; Kreiskrankenhaus Zwiesel: Dr. K. H. Hurka, Dr. C.
Propfe.
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